Hepatic Steatosis and Fibrosis in Chronic Hepatitis C in Taiwan

Total Page:16

File Type:pdf, Size:1020Kb

Hepatic Steatosis and Fibrosis in Chronic Hepatitis C in Taiwan Jpn. J. Infect. Dis., 60, 377-381, 2007 Original Article Hepatic Steatosis and Fibrosis in Chronic Hepatitis C in Taiwan Meng-Hsuan Hsieh1, Li-Po Lee2, Ming-Yen Hsieh2, Kun-Bow Tsai3, Jee-Fu Huang4, Nai-Jen Hou4, Shinn-Chern Chen2,5, Zu-Yau Lin2,5, Ming-Yuh Hsieh2,5, Liang-Yen Wang2,5, Chia-Yen Dai1,2,5,6*, Wan-Long Chuang2,5 and Ming-Lung Yu2,5 1Department of Occupational and Environmental Medicine, 3Department of Pathology, and 4Department of Internal Medicine, Kaohsiung Municipal HsiaoKang Hospital; 2Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; and 5Faculty of Internal Medicine and 6Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan (Received May 21, 2007. Accepted September 5, 2007) SUMMARY: Hepatitis C virus (HCV) infection has been associated with hepatic steatosis. However, the role of hepatic steatosis in the pathogenesis of HCV infection remains controversial. In our study, 425 consecutive HCV-viremic patients with biopsy-proven chronic hepatitis C (male, 264; mean age, 49.0 years) were enrolled. Scoring of hepatic steatosis was based on the method described by Kleiner and on histopathology performed using the Knodell and Scheuer systems. HCV RNA level and genotypes were determined at the time of biopsy. Hepatic steatosis was observed in 30.8% of patients, including 113 mild, 16 moderate, and 3 with severe hepatic steatosis. Patients with a body mass index (BMI) <23 kg/m2 had a significantly lower rate (18.9%) of hepatic steatosis (P < 0.001). Hepatic steatosis did not correlate with the hepatic necroinflammatory activity, but was related to hepatic fibrosis (P = 0.035). Hepatic steatosis was also not associated with HCV RNA level, and the distribution was similar between patients with HCV genotype 1 and genotype 2 infection. According to multivariate analysis, BMI is the strongest risk factor associated with hepatic steatosis, followed by hepatic fibrosis and triglyceride level with odds ratios (95% confidence intervals) of 2.51 (1.49-4.23), 2.06 (1.14-3.70), and 1.02 (1.01-1.03), respectively. Hepatic steatosis was associated with being overweight, hepatic fibrosis, and triglyceride level in chronic hepatitis C. (11,12). Given that hepatic steatosis may therefore be an INTRODUCTION important histopathological factor in CHC, the aim of this Hepatic steatosis is a pathological phenomenon whereby study was to establish the prevalence of hepatic steatosis in fat is deposited within hepatocytes. Many factors are known Taiwanese CHC patients and to evaluate whether hepatic to be risks for hepatic steatosis, including diabetes mellitus, steatosis was related to the virological characteristics of HCV hyperlipidaemia, certain drugs, and obesity (1,2). In recent and the histopathological features of liver biopsy. In addition, years, some studies have shown that chronic hepatitis C (CHC) the association between hepatic steatosis and anthropometric is also a risk factor, and indeed hepatic steatosis is associated and biometabolic markers in CHC patients was also explored. with CHC (3,4). Previous studies have shown that 30-70% of liver biopsies from patients with CHC include histological MATERIALS AND METHODS evidence of steatosis (5-7). Recent studies indicate that hepa- titis C virus (HCV) core protein has a direct inhibitory effect Patients: A total of 425 consecutive CHC patients were on the function of microsomal triglyceride transfer proteins enrolled at the Kaohsiung Municipal Hsiao-Kang Hospital related to the secretion of very low density lipoproteins (VLDL) (a regional core hospital) and Kaohsiung Medicine Univer- (8,9). Furthermore, HCV core protein is known to damage the sity Hospital (a medical center) from August 1998 to March mitochondria and therefore create oxidative stress within the 2005. They were all seropositive for antibody to HCV (anti- hepatocytes, a process that disrupts the peroxidation of fats HCV) for more than 6 months, and positive for HCV RNA. within hepatocytes and can lead to hepatic steatosis (5,8). All patients underwent liver biopsies and were proven to have In clinical observations, it remains controversial whether CHC. The patients’ medical histories were taken and their hepatic steatosis influences the progression of fibrosis in the body mass index (BMI) was measured on the date of their liver histopathology of CHC patients. Steatosis has been liver biopsy. Hypertension was determined according to the reported to be independently associated with fibrosis in CHC criteria defined by the National Committee on Prevention, (3,4); however, other studies have documented that steatosis Detection, Evaluation, and Treatment of High Blood Pressure is not associated with the presence of or subsequent progres- (13). Patients with diabetes mellitus were classified accord- sion to fibrosis in a cohort study group (10). Several HCV ing to the diagnostic criteria of the National Diabetes Data hyperendemic townships in southern Taiwan were found to Group (14), or if the patient’s past history mentioned taking have a prevalence of higher than 30% in previous studies oral hypoglycemic agents (OHA) or injecting insulin to con- trol blood sugar. Hyperlipidaemia was defined as the fasting *Corresponding author: Mailing address: Hepatobiliary Division, lipid criterion according to the third report of the National Department of Internal Medicine, Kaohsiung Medical Univer- Cholesterol Education Program (NCEP) Expert Panel on De- sity Hospital, 100 Tzyou 1st Rd, Kaohsiung City 807, Taiwan. tection, Evaluation, and Treatment of High Blood Choles- Tel: +886-7-3121101 ext. 7475, Fax: +886-7-3234553, E-mail: terol in Adults (Adult Treatment Panel III) final report (15). [email protected] Patients were classified as overweight if their BMI was greater 377 than or equal to 23 kg/m2, according to the Asia-Pacific BMI assay kits (Abbott, North Chicago, Ill., USA). HCV RNA was criteria (16). Patients were excluded if they were diagnosed detected using a standardized automated qualitative reverse with coexisting hepatocellular carcinoma, decompensated transcription-polymerase chain reaction (PCR) assay (COBAS cirrhosis or hepatic failure, other hepatic diseases (such as AMPLICOR Hepatitis C Virus Test, version 2.0; Roche, Wilson’s disease or α1-antitrypsin deficiency), biliary system Branchburg, N.J., USA), with a detection limit of 50 IU/mL. disease, pancreatic disease or other severe systemic diseases HCV RNA levels were detected with a branched DNA assay (such as renal failure), or if concurrent hepatitis B or human (Versant HCV RNA 3.0; Bayer, Emeryville, Calif., USA), immunodeficiency virus infection was present. Patients with performed strictly in accordance with the manufacturer’s a history of alcohol consumption exceeding 40 g/day or those instructions. Quantification was limited to 615 IU of HCV diagnosed with alcoholism, intravenous drug abuse, or expo- RNA per ml. HCV genotypes (1a, 1b, 2a, 2b, and 3a) were sure to hepatotoxic drugs were also excluded. determined through amplification of the core region using Liver histopathology: Liver biopsy samples of at least 2 genotype-specific primers (20). All data were collected at the cm in length were taken and stored –4°C in a refrigerator time of the liver biopsies. for 8 h, before being reversed in a freezer under –70°C. Statistical analysis: The statistical tests used were Student’s Biopsy samples were stained with hematoxylin and eosin, t test, the Mann-Whitney test, χ2 square test, and Fisher exact and the results were then reported by one pathologist. The test. All of these tests are two-sided, and the significance degree of hepatic necroinflammatory change was classified levels were set at α = 0.05. Logistic regression analysis was according to the histological activity index (HAI) score performed to determine the factors associated with hepatic system (17), and the fibrosis stage was set according to fibrosis based on the odds ratio and 95% confident intervals the Scheuer scale (18). The extent of hepatic steatosis was for these covariates. The covariates analyzed were age, sex, assessed by light microscopy and graded as none (0-5%), hypertension, diabetes mellitus, hyperlipidaemia, HCV geno- mild (5-33%), moderate (33-66%), and severe (>66%), type, HCV viral load, BMI, and hepatic necroinflammatory according to the area occupied by fatty hepatocytes (19). activity and fibrosis. The procedures were performed using the Laboratory tests: The presence of anti-HCV was tested SPSS 12.0 statistical package (SPSS, Inc., Chicago, Ill., USA). by using third generation enzyme-linked immunosorbent Table 1. Basic demographics and factors associated with steatosis and non-steatosis patients in chronic hepatitis C patients Patient Steatosis1) (–)Steatosis1) (+) Fibrosis2) (–) Fibrosis2) (+) P P No. (%) No. (%) No. (%) No. (%) No. (%) No. of case 425 (100) 293 (68.2) 132 (30.8) 91 (21.4) 334 (78.6) Age (y) (mean ± SD) 49.0 ± 12.2 49.2 ± 12.5 48.4 ± 11.7 0.48 42.5 ± 13.0 50.7 ± 11.4 0.027) Sex Male 264 (62.1) 177 (60.4) 87 (65.9) 0.28 64 (70.3) 200 (59.9) 0.07 Female 161 (37.9) 116 (39.6) 45 (34.1) 27 (29.7) 134 (40.1) Hypertension3) Without 357 (84.0) 250 (85.3) 107 (81.1) 0.27 83 (91.2) 274 (82.0) 0.037) With 68 (16.0) 43 (14.7) 25 (18.9) 8 (8.8) 60 (18.0) Diabetes mellitus4) Without 384 (90.4) 267 (91.1) 117 (88.6) 0.42 85 (93.4) 299 (89.5) 0.27 With 41 (9.6) 26 (8.9) 15 (11.4) 6 (6.6) 35 (10.5) Hyperlipidemia5) Without 407 (95.8) 282 (96.2) 125 (94.7) 0.46 85 (93.4)
Recommended publications
  • Primary Biliary Cholangitis: a Brief Overview Justin S
    REVIEW Primary Biliary Cholangitis: A Brief Overview Justin S. Louie,* Sirisha Grandhe,* Karen Matsukuma,† and Christopher L. Bowlus* Primary biliary cholangitis (PBC), previously referred to supported by the higher concordance of PBC in monozy- as primary biliary cirrhosis, is the most common chronic gotic compared with dizygotic twins.4 In addition, certain cholestatic autoimmune disease affecting adults in the human leukocyte antigen haplotypes have been associ- United States.1 It is characterized by a hallmark serologic ated with PBC, as well as variants at loci along the inter- signature, antimitochondrial antibody (AMA), and specific leukin-12 (IL-12) immunoregulatory pathway (IL-12A and bile duct pathology with progressive intrahepatic duct de- IL-12RB2 loci).5 struction leading to cholestasis. PBC is potentially fatal and can have both intrahepatic and extrahepatic complications. PATHOGENESIS EPIDEMIOLOGY The primary disease mechanism in PBC is thought to be T cell lymphocyte–mediated injury against intralobu- PBC affects all races and ethnicities; however, it is best lar biliary epithelial cells. This causes progressive destruc- studied in the Caucasian population. The condition pre- tion and eventual disappearance of the intralobular bile dominantly affects women older than 40 years, with a ducts. Molecular mimicry has been proposed as the ini- female/male ratio of 9:1.2 Although the incidence of PBC tiating event in the loss of tolerance primarily to mito- appears to be stable, the overall prevalence of the disease chondrial pyruvate dehydrogenase complex, E2, during is increasing.3 An individual’s genetic susceptibility, epige- which exogenous antigens evoke an immune response netic factors, and certain environmental triggers seem to that recognizes an endogenous (self) antigen inciting an play important roles.
    [Show full text]
  • Hepatitis A, B, and C: Learn the Differences
    Hepatitis A, B, and C: Learn the Differences Hepatitis A Hepatitis B Hepatitis C caused by the hepatitis A virus (HAV) caused by the hepatitis B virus (HBV) caused by the hepatitis C virus (HCV) HAV is found in the feces (poop) of people with hepa- HBV is found in blood and certain body fluids. The virus is spread HCV is found in blood and certain body fluids. The titis A and is usually spread by close personal contact when blood or body fluid from an infected person enters the body virus is spread when blood or body fluid from an HCV- (including sex or living in the same household). It of a person who is not immune. HBV is spread through having infected person enters another person’s body. HCV can also be spread by eating food or drinking water unprotected sex with an infected person, sharing needles or is spread through sharing needles or “works” when contaminated with HAV. “works” when shooting drugs, exposure to needlesticks or sharps shooting drugs, through exposure to needlesticks on the job, or from an infected mother to her baby during birth. or sharps on the job, or sometimes from an infected How is it spread? Exposure to infected blood in ANY situation can be a risk for mother to her baby during birth. It is possible to trans- transmission. mit HCV during sex, but it is not common. • People who wish to be protected from HAV infection • All infants, children, and teens ages 0 through 18 years There is no vaccine to prevent HCV.
    [Show full text]
  • Active Peptic Ulcer Disease in Patients with Hepatitis C Virus-Related Cirrhosis: the Role of Helicobacter Pylori Infection and Portal Hypertensive Gastropathy
    dore.qxd 7/19/2004 11:24 AM Page 521 View metadata, citation and similar papers at core.ac.uk ORIGINAL ARTICLE brought to you by CORE provided by Crossref Active peptic ulcer disease in patients with hepatitis C virus-related cirrhosis: The role of Helicobacter pylori infection and portal hypertensive gastropathy Maria Pina Dore MD PhD, Daniela Mura MD, Stefania Deledda MD, Emmanouil Maragkoudakis MD, Antonella Pironti MD, Giuseppe Realdi MD MP Dore, D Mura, S Deledda, E Maragkoudakis, Ulcère gastroduodénal évolutif chez les A Pironti, G Realdi. Active peptic ulcer disease in patients patients atteints de cirrhose liée au HCV : Le with hepatitis C virus-related cirrhosis: The role of Helicobacter pylori infection and portal hypertensive rôle de l’infection à Helicobacter pylori et de la gastropathy. Can J Gastroenterol 2004;18(8):521-524. gastropathie liée à l’hypertension portale BACKGROUND & AIM: The relationship between Helicobacter HISTORIQUE ET BUT : Le lien entre l’infection à Helicobacter pylori pylori infection and peptic ulcer disease in cirrhosis remains contro- et l’ulcère gastroduodénal dans la cirrhose reste controversé. Le but de la versial. The purpose of the present study was to investigate the role of présente étude est de vérifier le rôle de l’infection à H. pylori et de la gas- H pylori infection and portal hypertension gastropathy in the preva- tropathie liée à l’hypertension portale dans la prévalence de l’ulcère gas- lence of active peptic ulcer among dyspeptic patients with compen- troduodénal évolutif chez les patients dyspeptiques souffrant d’une sated hepatitis C virus (HCV)-related cirrhosis.
    [Show full text]
  • Understanding Human Astrovirus from Pathogenesis to Treatment
    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 6-2020 Understanding Human Astrovirus from Pathogenesis to Treatment Virginia Hargest University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Diseases Commons, Medical Sciences Commons, and the Viruses Commons Recommended Citation Hargest, Virginia (0000-0003-3883-1232), "Understanding Human Astrovirus from Pathogenesis to Treatment" (2020). Theses and Dissertations (ETD). Paper 523. http://dx.doi.org/10.21007/ etd.cghs.2020.0507. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Understanding Human Astrovirus from Pathogenesis to Treatment Abstract While human astroviruses (HAstV) were discovered nearly 45 years ago, these small positive-sense RNA viruses remain critically understudied. These studies provide fundamental new research on astrovirus pathogenesis and disruption of the gut epithelium by induction of epithelial-mesenchymal transition (EMT) following astrovirus infection. Here we characterize HAstV-induced EMT as an upregulation of SNAI1 and VIM with a down regulation of CDH1 and OCLN, loss of cell-cell junctions most notably at 18 hours post-infection (hpi), and loss of cellular polarity by 24 hpi. While active transforming growth factor- (TGF-) increases during HAstV infection, inhibition of TGF- signaling does not hinder EMT induction. However, HAstV-induced EMT does require active viral replication.
    [Show full text]
  • Hepatitis C 2005 Clinical Guidelines Summary of The: New York State Department of Health Clinical Guidelines for the Medical Management of Hepatitis C
    Hepatitis C 2005 Clinical Guidelines Summary of the: New York State Department of Health Clinical Guidelines for the Medical Management of Hepatitis C Inside: Key Features of Viral Hepatitis A,B and C 1 Natural Course of HCV Infection 2 Persons at Risk for HCV Infection 3 Sources of HCV Infection 4 Counseling Prior To Testing 5 Screening for HCV Algorithm 6 Laboratory Testing for HCV 7 Interpretation of HCV Test Results 8 Post Exposure Screening for HCV 9 Counseling After Testing 10 Treating HCV Patients 11 Medical Management of HCV Positive Patients 12 References and Internet Resources 13 Hepatitis C Virus The Hidden Epidemic The Burden of HCV • 3 million Americans are chronically infected with the • 8-10,000 deaths a year are caused by HCV. Hepatitis C virus (HCV). • HCV is the leading cause for liver transplants and • 342,000 New Yorkers are estimated to be infected chronic liver disease. with HCV. • HCV deaths will increase four-fold to 38,000, by • A majority of the people infected with HCV do not the year 2010. know they have it. • Years of life lost to Hepatitis C (2001-2019) • Thousands of people go undetected each year—due 3.1 million years to inadequate risk assessment, under-screening and confusion about the use of diagnostic tests. • Cost of premature disability and death (2010-2109) $75.5 billion Hepatitis C Virus • Direct medical costs in absentee losses due to Hepatitis C $750 million/ year • HCV is a blood-borne disease transmitted by • Total medical expenditures for persons with HCV blood-to-blood contact.
    [Show full text]
  • Hepatitis C Virus Infection and Human Pancreatic ß-Cell Dysfunction
    Pathophysiology/Complications BRIEF REPORT Hepatitis C Virus Infection and Human Pancreatic ␤-Cell Dysfunction 1 1 MATILDE MASINI, MD SILVIA DEL GUERRA, PHD showing the characteristic insulin gran- 2 1 DANIELA CAMPANI, MD MARCO BUGLIANI, PHD ules and normally preserved mitochon- 3 1 UGO BOGGI, MD SCILLA TORRI, PHD ␤ 2 1 dria. In -cells from HCV-positive MICHELE MENICAGLI, MD STEFANO DEL PRATO, MD 1 3 pancreases, the presence of virus-like par- NICOLA FUNEL, MD FRANCO MOSCA, MD 1 4 ticles was observed, mainly close to the MARIA POLLERA, MD FRANCO FILIPPONI, MD 1 1 membranes of Golgi apparatus, which, in ROBERTO LUPI, PHD PIERO MARCHETTI, MD, PHD turn, appeared hyperplastic and dilated (Fig. 1D). The mitochondria appeared round-shaped with dispersed matrix and fragmented cristae (Fig. 1D). Additional Ϯ 2 any patients with chronic hepati- and 2 women, BMI 25.8 1.6 kg/m ) ␤-cell changes were observed at the Ϯ tis C virus (HCV) develop type 2 and 10 HCV-negative (age 67 9 years, level of rough endoplasmic reticulum, Ϯ diabetes (1). This prevalence is 6 men and 4 women, BMI 26.8 2.0 which showed long and dilated tubular M 2 much higher than that observed in the kg/m ) donors were harvested and stud- membranes, with numerous electron- general population and in patients with ied with the approval of our local ethics dense ribosomes bound to the latter (not other chronic liver diseases such as hepa- committee. Histological studies were shown). These morphological changes titis B virus, alcoholic liver disease, and performed by immunohistochemistry were accompanied by reduced in vitro primary biliary cirrhosis.
    [Show full text]
  • Non-Alcoholic Fatty Liver Disease
    Non-alcoholic fatty liver disease Description Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat. The fat deposits in the liver associated with NAFLD usually cause no symptoms, although they may cause increased levels of liver enzymes that are detected in routine blood tests. Some affected individuals have abdominal pain or fatigue. During a physical examination, the liver may be found to be slightly enlarged. Between 7 and 30 percent of people with NAFLD develop inflammation of the liver (non- alcoholic steatohepatitis, also known as NASH), leading to liver damage. Minor damage to the liver can be repaired by the body. However, severe or long-term damage can lead to the replacement of normal liver tissue with scar tissue (fibrosis), resulting in irreversible liver disease (cirrhosis) that causes the liver to stop working properly. Signs and symptoms of cirrhosis, which get worse as fibrosis affects more of the liver, include fatigue, weakness, loss of appetite, weight loss, nausea, swelling (edema), and yellowing of the skin and whites of the eyes (jaundice). Scarring in the vein that carries blood into the liver from the other digestive organs (the portal vein) can lead to increased pressure in that blood vessel (portal hypertension), resulting in swollen blood vessels (varices) within the digestive system.
    [Show full text]
  • Vaccinations for Adults with Chronic Liver Disease Or Infection
    Vaccinations for Adults with Chronic Liver Disease or Infection This table shows which vaccinations you should have to protect your health if you have chronic hepatitis B or C infection or chronic liver disease (e.g., cirrhosis). Make sure you and your healthcare provider keep your vaccinations up to date. Vaccine Do you need it? Hepatitis A Yes! Your chronic liver disease or infection puts you at risk for serious complications if you get infected with the (HepA) hepatitis A virus. If you’ve never been vaccinated against hepatitis A, you need 2 doses of this vaccine, usually spaced 6–18 months apart. Hepatitis B Yes! If you already have chronic hepatitis B infection, you won’t need hepatitis B vaccine. However, if you have (HepB) hepatitis C or other causes of chronic liver disease, you do need hepatitis B vaccine. The vaccine is given in 2 or 3 doses, depending on the brand. Ask your healthcare provider if you need screening blood tests for hepatitis B. Hib (Haemophilus Maybe. Some adults with certain high-risk conditions, for example, lack of a functioning spleen, need vaccination influenzae type b) with Hib. Talk to your healthcare provider to find out if you need this vaccine. Human Yes! You should get this vaccine if you are age 26 years or younger. Adults age 27 through 45 may also be vacci- papillomavirus nated against HPV after a discussion with their healthcare provider. The vaccine is usually given in 3 doses over a (HPV) 6-month period. Influenza Yes! You need a dose every fall (or winter) for your protection and for the protection of others around you.
    [Show full text]
  • Dyspepsia in Cirrhotic Hepatitis C Patients
    Journal of Rawalpindi Medical College (JRMC); 2017;21(4): 321-324 Original Article Dyspepsia in Cirrhotic Hepatitis C Patients Maryam Jalil1, Faiza Aslam 2, Talal Khurshid Bhatti 3 , Muhammad Umar 1 , Hamamatul Bushra Khaar 1 1Woman Medical Officer,THQ Hospital ,Fateh Jang;2. Research Coordinator at Research Unit, Rawalpindi Medical University; 3. Medical officer, THQ Hospital,Lalamusa. Abstract positive individuals and patients with liver cirrhosis.2 Indigestion, also known as dyspepsia, is a condition of Background:To determine the frequency of impaired digestion characterized by upper abdominal patients with dyspepsia, its patterns of presentation fullness, heartburn, nausea, belching, upper and causes along with their associations with gender abdominal pain, regurgitation, or water brash (bitter and age, amongst HCV cirrhotic patients presenting tasting liquid coming up into back of throat).3About to a tertiary care health facility of Rawalpindi. 30-40% of all adults experience symptoms of Methods: In this cross sectional study 207 HCV dyspepsia but organic cause is found in only few cases cirrhotic patients,above 25 years of age irrespective who seek medical care. The remaining cases are of gender, were included. Patients receiving labelled as having functional dyspepsia.4 Different prolonged treatment of acid suppression prior to causes of dyspepsia are gastroesophageal reflux hospitalization were excluded. After taking history disease (GERD), peptic ulcer, gastrointestinal cancers, and performing thorough physical examination, gastritis, hiatal hernia, gastroparesis, congestive routine laboratory investigations, abdominal gastropathy, cholelithiasis, food or drug intolerance ultrasonography and endoscopies were performed to and other diseases of gastrointestinal tract, liver, determine the cause of dyspepsia. pancreas and other systems.5-7 Results:Amongst 207 HCV cirrhotic patients 146 World Health Organization Statistics 2008 lists (70.5%) were presented with dyspepsia.
    [Show full text]
  • Non-Alcoholic Fatty Liver Disease Information for Patients
    April 2021 | www.hepatitis.va.gov Non-Alcoholic Fatty Liver Disease Information for Patients What is Non-Alcoholic Fatty Liver Disease? Losing more than 10% of your body weight can improve liver inflammation and scarring. Make a weight loss plan Non-alcoholic fatty liver disease or NAFLD is when fat is with your provider— and exercise to keep weight off. increased in the liver and there is not a clear cause such as excessive alcohol use. The fat deposits can cause liver damage. Exercise NAFLD is divided into two types: simple fatty liver and non- Start small, with a 5-10 minute brisk walk for example, alcoholic steatohepatitis (NASH). Most people with NAFLD and gradually build up. Aim for 30 minutes of moderate have simple fatty liver, however 25-30% have NASH. With intensity exercise on most days of the week (150 minutes/ NASH, there is inflammation and scarring of the liver. A small week). The MOVE! Program is a free VA program to help number of people will develop significant scarring in their lose weight and keep it off. liver, called cirrhosis. Avoid Alcohol People with NAFLD often have one or more features of Minimize alcohol as much as possible. If you do drink, do metabolic syndrome: obesity, high blood pressure, low HDL not drink more than 1-2 drinks a day. Patients with cirrhosis cholesterol, insulin resistance or diabetes. of the liver should not drink alcohol at all. NAFLD increases the risk for diabetes, cardiovascular disease, Treat high blood sugar and high cholesterol and kidney disease. Ask your provider if you have high blood sugar or high Most people feel fine and have no symptoms.
    [Show full text]
  • Hepatitis C Fact Sheet
    Hepatitis C Fact Sheet What is Hepatitis C? Hepatitis C is a liver disease caused by the hepatitis C virus (HCV), which is found in the blood of persons who have this disease. HCV is spread primarily by contact with the blood of an infected person. Hepatitis C is not spread by sneezing, coughing, hugging, sharing eating utensils or drinking glasses, or other casual contact. Hepatitis C is not spread by food or water. How serious is Hepatitis C? Hepatitis C infection can range in severity from no symptoms to chronic liver damage. Although many individuals never feel sick from the disease, HCV can remain as a lifelong infection. In some cases, individuals with hepatitis C may develop long term complications cirrhosis (scarring) of the liver and liver failure. What are the symptoms of hepatitis C? Most people infected with HCV do not have symptoms for years, even decades, following infection. Symptom onset is slow beginning with fatigue, nausea and loss of appetite, stomach pain, diarrhea and fever. Other symptoms include dark or brown urine, light-colored stools and yellowish eyes and skin. Hepatitis C Fact Sheet How is hepatitis C spread from one person to another? HCV is spread primarily by direct contact with human blood. People at increased risk for hepatitis C include: • Injecting drug users • Hemodialysis patients • Health care workers • Sexual contacts of infected persons • Persons with multiple sex partners • Recipient of transfusions before July, 1992 • Recipient of clotting factors made before 1987 What is the risk of hepatitis C transmission from an HCV infected mother to her baby? Approximately 5% of infants born to HCV infected women contract Hepatitis C.
    [Show full text]
  • Hepatitis C Virus Infection December 2017
    . Europe’s journal on infectious disease epidemiology, prevention and control Special edition: Hepatitis C virus infection December 2017 Featuring • Hepatitis C virus seroprevalence and prevalence of chronic infection in the adult population in Ireland: a study of residual sera, April 2014 to February 2016 • Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions www.eurosurveillance.org Editorial team Editorial advisors Based at the European Centre for Albania: Alban Ylli, Tirana Disease Prevention and Control (ECDC), Austria: Maria Paulke-Korinek, Vienna 171 65 Stockholm, Sweden Belgium: Koen de Schrijver; Tinne Lernout, Antwerp Telephone number Bosnia and Herzegovina: Sanjin Musa, Sarajevo +46 (0)8 58 60 11 38 Bulgaria: Iva Christova, Sofia E-mail Croatia: Sanja Music Milanovic, Zagreb [email protected] Cyprus: Maria Koliou, Nicosia Czech Republic: Jan Kynčl, Prague Editor-in-chief Denmark: Peter Henrik Andersen, Copenhagen Dr Ines Steffens Estonia: Kuulo Kutsar, Tallinn Senior editor Finland: Outi Lyytikäinen, Helsinki Kathrin Hagmaier France: Judith Benrekassa, Paris Germany: Jamela Seedat, Berlin Scientific editors Greece: Rengina Vorou, Athens Janelle Sandberg Hungary: Ágnes Hajdu, Budapest Karen Wilson Iceland: Gudrun Sigmundsdottir, Reykjavík Assistant editors Ireland: Lelia Thornton, Dublin Alina Buzdugan Italy: Paola De Castro, Rome Vilasini Roy Latvia:
    [Show full text]